Comparing Malaria Treatments: Cotrifazid vs. Mefloquine and Quinine
Author Information
Author(s): Genton Blaise, Mueller Ivo, Betuela Inoni, Casey Gerard, Ginny Meza, Alpers Michael P, Reeder John C
Primary Institution: Swiss Tropical Institute, Basel, Switzerland
Hypothesis
Is Cotrifazid as effective and safe as mefloquine or quinine plus sulfadoxine-pyrimethamine for treating drug-resistant malaria?
Conclusion
Cotrifazid shows short-term clinical equivalence to mefloquine and quinine plus SP, but has a higher rate of parasitological failure.
Supporting Evidence
- Cotrifazid had a lower incidence of adverse events compared to mefloquine and quinine + SP.
- Clinical failure rates were low across all treatment groups.
- Parasitological failure rates were significantly higher in the Cotrifazid group.
- The study included a diverse patient population from multiple health facilities.
- The trial was designed to assess both safety and efficacy of the treatments.
Takeaway
This study tested a new malaria treatment called Cotrifazid against two other treatments. While it worked well for symptoms, it didn't clear the malaria parasites as effectively.
Methodology
A multicentric, open-label, block-randomized trial comparing Cotrifazid, mefloquine, and quinine + SP in patients with uncomplicated malaria.
Potential Biases
Potential bias due to open-label design and short follow-up period.
Limitations
Follow-up was only for 14 days, which may not capture all treatment failures.
Participant Demographics
Patients of all ages with recurrent uncomplicated malaria; median age around 7 years.
Statistical Information
P-Value
0.02
Statistical Significance
p = 0.02
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website